Global Molecular Diagnostics for Infectious Disease Market Report 2021-2025: Microbiology Lab May Disappear While Multiplex Takes Center Stage

Dublin, May 05, 2021 (GLOBE NEWSWIRE) -- The "Molecular Diagnostics for Infectious Disease 2021-2025: Market Analysis by Syndrome, Plex, Place, and Country with COVID-19 Impact & Forecast, Executive Guides, and Customization" report has been added to ResearchAndMarkets.com's offering.

COVID-19 Drives a Surge in Demand, But What is the Long Term Impact? The Microbiology Lab May Disappear While Multiplex Takes Center Stage

The Molecular Diagnostics - Infectious Disease sector of the clinical diagnostics industry is poised for record growth. A market that just keeps on growing but is spiking as an enormous C19Dx demand sweeps over the globe.

Find out what the numbers are in this informative report, and find out about the exciting developments in multiplex assays which threaten to change diagnosis and treatment while limiting the threat of anti microbial drug resistance.

Infectious disease testing directly benefits from the explosion in biotechnology, especially genomics. Learn all about it in this new report.

A range of dynamic trends are pushing market growth and company valuations.

Trends like:

• Multiplex testing;

• Pathogen evolution and pandemics;

• Biotechnology advances in genetics;

• Climate change;

• Globalization;

• The rise of rapid testing.

Exciting technical developments especially in the seesaw between nucleic acid testing and immunoassay, hold the promise of a dynamic, growing and evolving world market that holds the promise of diagnostics taking the lead in infectious disease eradication.

The report has hundreds of pages of information including a complete list of Current 2020 United States Medicare Fee Payment Schedules to help sharpen your pricing. Again, assistance in using the information is normally provided without additional charges. The report includes detailed breakouts for 15 Countries and 4 Regions. A detailed breakout for any country in the world is available.

Key Topics Covered:

1 Molecular Diagnostics of Infectious Disease - Strategic Situation Analysis and Impact of COVID-19

2 Guide for Executives, Marketing, Sales and Business Development Staff

3 Guide for Management Consultants and Investment Advisors

4 Introduction and Market Definition
4.1 What is Molecular Diagnostics
4.2 The Diagnostics Revolution
4.3 Market Definition
4.3.1 Revenues
4.4 Methodology
4.5 U.S. Medical Market and Clinical Laboratory Testing - Perspective
4.5.1 U.S. Medicare Expenditures for Clinical Testing

5 The Infectious Diseases - Market Analysis by Disease
5.1 HIV - Human Immunodeficiency Virus (AIDS)
5.1.1 Virology
5.1.1.1 Classification
5.1.1.2 Structure and genome
5.1.1.3 Tropism
5.1.1.4 Replication cycle
5.1.1.5 Genetic variability
5.1.2 Diagnosis
5.1.3 Testing
5.1.3.1 Antibody tests
5.1.3.2 Point of Care Tests (POCT)
5.1.3.3 Antigen Tests
5.1.3.4 Nucleic acid-based tests (NAT)
5.1.3.5 Other tests used in HIV treatment
5.1.4 Market Opportunity Analysis
5.2 HBV - Hepatitis B
5.2.1 Virology
5.2.1.1 Genome
5.2.1.2 Pathogenesis
5.2.1.3 Hepatitis B virus replication
5.2.1.4 Serotypes and genotypes
5.2.2 Mechanisms
5.2.3 Diagnosis
5.2.4 Market Opportunity Analysis
5.3 HCV - Hepatitis C
5.3.1 Taxonomy
5.3.2 Structure
5.3.2.1 Genome
5.3.3 Molecular biology
5.3.4 Replication
5.3.5 Genotypes
5.3.5.1 Clinical importance
5.3.6 Market Opportunity Analysis
5.4 HPV - Human papillomavirus
5.4.1 Virology
5.4.1.1 E6/E7 proteins
5.4.1.2 Role in cancer
5.4.1.3 E2 research
5.4.1.4 Latency period
5.4.1.5 Clearance
5.4.2 Diagnosis
5.4.2.1 Cervical testing
5.4.2.2 Oral testing
5.4.2.3 Testing men
5.4.2.4 Other testing
5.4.3 Market Opportunity Analysis
5.5 Influenza
5.5.1 Virology
5.5.1.1 Types of virus
5.5.1.2 Influenzavirus A
5.5.1.3 Influenzavirus B
5.5.1.4 Influenzavirus C
5.5.1.5 Structure, properties, and subtype nomenclature
5.5.1.6 Replication
5.5.2 Testing
5.5.2.1 Advantages/Disadvantages of Molecular Assays
5.5.3 Market Opportunity Analysis
5.6 CTGC - Chlamydia/Gonorhea
5.6.1 Gonorrhea
5.6.1.1 Diagnosis
5.6.1.2 Screening
5.6.2 Chlamydia
5.6.2.1 Diagnosis
5.6.2.2 Screening
5.6.3 Testing
5.6.3.1 Nucleic acid amplification tests (NAATs)
5.6.3.2 Performance of NAAT Tests
5.6.4 Market Opportunity Analysis
5.7 Tuberculosis
5.7.1 Mycobacteria
5.7.2 Diagnosis
5.7.2.1 Active tuberculosis
5.7.2.2 Latent tuberculosis
5.7.3 Epidemiology
5.7.4 Molecular Diagnostic Tests
5.7.5 Market Opportunity Analysis
5.8 MRSA - Methicillin-resistant Staphylococcus aureus
5.8.1 Diagnosis
5.8.2 FDA Approved Molecular Tests
5.8.3 Market Opportunity Analysis
5.9 VRE - Vancomycin-resistant Enterococcus
5.9.1 FDA Approved MDx Tests for VRE
5.9.2 Market Opportunity Analysis
5.10 Blood Screening
5.10.1 Collection and Testing
5.10.2 FDA Approved Multiplex Assays
5.10.3 Market Opportunity Analysis
5.11 COVID-19
5.11.1 Signs and symptoms
5.11.2 Transmission
5.11.3 Diagnosis
5.11.4 Prevention
5.11.5 Management
5.11.6 Prognosis
5.12 Pandemic Diagnostics
5.12.1 Risk Management - Spark and Spread
5.12.2 Dx Technology - Nucleic Acid Based
5.12.3 Dx Technology - Immunoassay & Serology
5.12.4 Time to Market and Preparedness Issues
5.12.5 Unrecognized Role of Multiplex in Pandemic Management

6 Industry Overview
6.1 Players in a Dynamic Market
6.1.1 Academic Research Lab
6.1.2 Diagnostic Test Developer
6.1.3 Instrumentation Supplier
6.1.4 Distributor and Reagent Supplier
6.1.5 Independent Testing Lab
6.1.6 Public National/Regional Lab
6.1.7 Hospital lab
6.1.8 Physician Office Labs
6.1.9 Audit Body
6.1.10 Certification Body
6.2 The Clinical Laboratory Market Segments
6.2.1 Traditional Market Segmentation
6.2.2 Laboratory Focus and Segmentation
6.3 Industry Structure
6.3.1 Hospital Testing Share
6.3.2 Economies of Scale
6.3.2.1 Hospital vs. Central Lab
6.3.3 Physician Office Labs
6.3.4 Physicians and POCT

7 Profiles of Key MDx Companies
7.1 Abacus Diagnostica
7.2 Abbott Diagnostics
7.3 Accelerate Diagnostics
7.4 Ador Diagnostics
7.5 Akonni Biosystems
7.6 Alveo Technologies
7.7 Applied BioCode
7.8 Aus Diagnostics
7.9 Beckman Coulter Diagnostics
7.10 Becton, Dickinson and Company
7.11 Binx Health
7.12 Biocartis
7.13 bioMerieux Diagnostics
7.14 Bio-Rad Laboratories, Inc.
7.15 Bosch Healthcare Solutions GmbH
7.16 Cepheid (now Danaher)
7.17 Chembio
7.18 Co-Diagnostics
7.19 Credo Diagnostics Biomedical
7.20 Cue Health
7.21 Curetis N.V./Curetis GmbH
7.22 Diagenode Diagnostics
7.23 Diascopic
7.24 Diasorin S.p.A.
7.25 Eiken Chemical
7.26 Enzo Life Sciences, Inc.
7.27 Eurofins Scientific
7.28 Fluxergy
7.29 Fulgent Genetics
7.30 Fusion Genomics
7.31 Genedrive
7.32 Genetic Signatures
7.33 GenMark Dx
7.34 Grifols
7.35 Hibergene Diagnostics
7.36 Hologic
7.37 Illumina
7.38 Immunexpress
7.39 Inflammatix
7.40 Invetech
7.41 Janssen Diagnostics
7.42 Karius
7.43 Lexagene
7.44 LightDeck Diagnostics
7.45 Luminex Corp.
7.46 Lumos Diagnostics
7.47 Mammoth Biosciences
7.48 Maxim Biomedical
7.49 Meridian Bioscience
7.50 Mesa Biotech
7.51 Millipore Sigma
7.52 Mindray
7.53 Mobidiag
7.54 Nanomix
7.55 Operon
7.56 Oxford Nanopore Technologies
7.57 Panagene
7.58 Perkin Elmer
7.59 Primerdesign
7.60 Prominex
7.61 Qiagen GmbH
7.62 QuantuMDx
7.63 Quidel
7.64 Roche Molecular Diagnostics
7.65 Saw Diagnostics
7.66 Seegene
7.67 Siemens Healthineers
7.68 Sona Nanotech
7.69 SpeeDx
7.70 T2 Biosystems
7.71 Thermo Fisher Scientific Inc.
7.72 Veramarx
7.73 Veredus Laboratories
7.74 Vir
7.75 XCR Diagnostics

8 Market Trends
8.1 Factors Driving Growth
8.1.1 New Genotypes Creating New Markets
8.1.2 Aging Population a Boon for All Diagnostics
8.1.3 Developing World Driving ID Dx Growth
8.1.4 Point of Care - Why Centralization is Losing Steam
8.1.5 Self Testing
8.1.6 The Need for Speed
8.1.7 The COVID Pandemic
8.2 Factors Limiting Growth
8.2.1 Lower Costs
8.2.2 Infectious Disease is Declining
8.2.3 Wellness Hurts
8.2.4 Economic Growth improves Living Standards
8.3 Instrumentation and Automation
8.3.1 Instruments Key to Market Share
8.3.2 The Shrinking Machine
8.3.3 Multiplex, Point of Care and The Speed Factor
8.4 Diagnostic Technology Development
8.4.1 The Sepsis Testing Market - A New Direction?
8.4.2 POCT/Self Testing as a Disruptive Force
8.4.3 The Genetics Play - One Test for All Known Infections
8.4.4 Antibiotic Resistance Genes - Simplifying Diagnostics

9 Molecular Dx - Infectious Disease Recent Developments
9.1 Recent Developments - Importance and How to Use This Section
9.1.1 Importance of These Developments
9.1.2 How to Use This Section
9.2 Roche to Acquire GenMark Diagnostics for $1.8B
9.3 Lucira Health Focuses on User Friendly Approach to Home Testing
9.4 Infectious Disease Dx Firm Talis Biomedical Raises $254M in IPO
9.5 Fluidigm Plans 'Durable' Diagnostics, Clinical Business
9.6 Thermo Fisher Scientific to Acquire Mesa Biotech for Up to $550M
9.7 Mammoth Biosciences Developing Pathogen Detection Tech
9.8 Illumina, IDbyDNA Developing Sequencing-Based Respiratory Tests
9.9 Scanogen Developing 90 Minute Infection Test
9.10 Malaria Assays Use CRISPR for Point-of-Care Multispecies Detection
9.11 FDA Provides Self Testing SARS-CoV-2 EAU Guidance
9.12 Mammoth Biosciences Announces Rapid, CRISPR-Based COVID-19 Diagnostic
9.13 Genetic Signatures Gets CE Mark for Coronavirus Molecular Test
9.14 Qiagen Respiratory Panel with Coronavirus Receives CE Mark
9.15 Lumos Diagnostics Closes $15M Series A Funding
9.16 Fusion Genomics to Assess NGS-Based Respiratory Tract Infection Assay
9.17 New Genomic Tests Diagnose Deadly Infections Faster
9.18 Biotia Raises $2.4M Seed Round
9.19 STDs resurge in US
9.20 Ares Genetics signs R&D agreement with leading global IVD corporation
9.21 Cell-Free DNA Used for Infectious Disease Testing
9.22 One BioMed Raises $5M

For more information about this report visit https://www.researchandmarkets.com/r/tnqxeo

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900